Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chrysojasminum subhumile

ABSTRACT: Chrysojasminum subhumile Genome sequencing

PROVIDER: PRJNA842199 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19448979_1.fastq.gz	Fastqsanger.gz
	SRR19448979_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

Chrysojasminum fruticans

Project description:Chrysojasminum fruticans haplotype 2 genome sequencing

| PRJNA1010724 | ENA

Chrysojasminum fruticans

Project description:Chrysojasminum fruticans haplotype 1 genome sequencing

| PRJNA1010725 | ENA

Chrysojasminum bignoniaceum

Project description:Chrysojasminum bignoniaceum haplotype 2 genome sequencing

| PRJNA1010755 | ENA

Chrysojasminum bignoniaceum

Project description:Chrysojasminum bignoniaceum haplotype 1 genome sequencing

| PRJNA1010756 | ENA

Chrysojasminum fruticans

Project description:Chrysojasminum fruticans overview

| PRJNA1191594 | ENA

Chrysojasminum bignoniaceum

Project description:Chrysojasminum bignoniaceum overview

| PRJNA1191601 | ENA

Project description:Chrysojasminum bignoniaceum genome sequencing

| PRJNA1031642 | ENA

Project description:Chrysojasminum fruticansgenome sequencing

| PRJNA1031632 | ENA

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc

Phytochemical analysis and antioxidant efficacy of <i>Chrysojasminum fruticans</i> (L.) Banfi in Syrian flora.

Project description:This study investigates the antioxidant properties of Chrysojasminum fruticans (L.) Banfi through a series of assays to measure the total phenolic content (TPC), total flavonoid content (TFC), and free radical scavenging activity using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay, to ensure that it can be used as an antioxidant drug. The TPC, TFC and DPPH assay were performed using spectrophotometric method, and in terms of a linear standard curve for gallic acid, Quercetin, Vitamin C respectively. The. aqueous extract of the flowers exhibited the highest concentration of phenolics, reaching 81.9 mg GAE (Gallic Acid Equivalent) per gram of (Dry Extract) DE, Conversely the ethanolic extract from the fruits demonstrated the lowest phenolic content, with a mere 0.249 (mg GAE/g DE). the aqueous flower extract demonstrated the highest flavonoid concentration, achieving an impressive 113.584 mg quercetin equivalents per gram of DE (mg QUE/g DE). In contrast, the methanolic fruit extract exhibited the lowest flavonoid concentration, measured at a mere 0.695 (mg QUE/g DE). Additionally, the methanolic flower extract demonstrated superior free radical scavenging activity, requiring only 0.348 mg/mL to inhibit 50 % of DPPH radicals, Conversely, the methanolic fruit extract exhibited the least antioxidant activity, as reflected by its highest IC50 value of 1.996 mg/mL. These results underscore Chrysojasminum fruticans (L.) Banfi potent antioxidant capacity and its established role in traditional medicine practices globally, and encourage to be included as a drug contributing to the treatment of many chronic diseases such as diabetes and cardiovascular diseases, after conducting the necessary clinical studies.

| S-EPMC11408042 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data